Oblique Therapeutics | Publications, conferences & press | Oblique Therapeutics

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Governance
Investors Relations
- Financial Reports
  - Annual Reports for the years 2016-2019
News
- Press Releases
- Publications, conferences & press
Contact

Oblique Therapeutics > Investors Relations > Publications, conferences & press

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Governance
Investors Relations
- Financial Reports
  - Annual Reports for the years 2016-2019
News
- Press Releases
- Publications, conferences & press
Contact

Copyright © 2021 Oblique Therapeutics AB.

Contact

Oblique Therapeutics AB
info@obliquet.com

Gothenburg
Arvid Wallgrens Backe 20
413 46 Göteborg
Sweden

Stockholm
Döbelnsgatan 64
113 52 Stockholm
Sweden

Menu

Home Page
About us
- Overview
- Organization
Technology
- Abiprot^TM-antibody platform
- Abiprot Select^TM
Portfolio
Corporate Governance
Investors Relations
- Financial Reports
  - Annual Reports for the years 2016-2019
News
- Press Releases
- Publications, conferences & press
Contact

About

Oblique Therapeutics is a privately held Swedish biotech developing innovative new medicines for severe diseases with a large unmet medical need focusing on pain, and advanced cancer. The company uses AbiprotTM, an in-house-invented, next-generation antibody platform that can generate antibodies with programmed function against the full human proteome.